16 results about "Pulmonary metastasis" patented technology

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating triple negative breast cancer and application thereof. The traditional Chinese medicine composition is prepared from the following main active ingredients in parts by mass: 20 to 40 parts of radix astragali seu hedysari, 10 to 20 parts of rhizoma curcumae, 10 to 20 parts of herba hedyotidis diffusae, 5 to 15 parts of fructus aurantii immaturus, 5 to 15 parts of radix bupleuri, 5 to 15 parts of radix paeoniae alba and 5 to 15 parts of liquorice root. Animal experiments show that the traditional Chinese medicine composition can significantly inhibit tumor growth and pulmonary metastasis of triple-negative breast cancer tumor-bearing mice, increase the proportion of CD8 + T lymphocytes in blood, reduce the proportion of MDSCs, significantly down-regulate the expression of pro-inflammatory cytokines such as IL-6, IL-1alpha, CXCL1 and GM-CSF in serum, and cooperate with PD-L1 immunotherapy to achieve a synergistic effect. And the whole blood and liver and kidney function indexes are in a normal range. Therefore, the traditional Chinese medicine composition disclosed by the invention can be used for effectively inhibiting the tumor growth and pulmonary metastasis of the triple negative breast cancer, remodeling the immune state of an organism and reducing the release of proinflammatory factors, and is safe, reliable, free of obvious liver and kidney toxicity and blood toxicity and small in side effect.

The invention discloses a formula for reducing phlegm and resolving masses, and a preparation method and application of freeze-dried powder of the formula for reducing phlegm and resolving masses, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition inhibits triple negative breast cancer adhesion-metastasis by regulating an FAK / SRC pathway, and comprises the following components by weight: 10-20 g of poria cocos, 10-20 g of rhizoma bolbostemmae, 10-20 g of radix trichosanthis, 5-12 g of curcuma zedoary, 10-20 g of selfheal, 10-20 g of oyster (smashed and decocted first), and 5-12 g of uniflower swisscentaury root. In-vitro experiments show that HTSJF can inhibit TNBC cell invasion, migration and adhesion (P is less than 0.01) in a dose-dependent manner, and along with reduction of the phosphorylation level of an FAK / SRC pathway, it is prompted that HTSJF inhibits TNBC transfer by regulating the pathway. In-vivo experiments prove that the HTSJF can obviously inhibit the reduction of TNBC pulmonary metastasis focus (P is less than 0.05) and recover part of normal pulmonary alveolar structures, and the inhibition effect of the HTSJF on TNBC pulmonary metastasis is further proved.

The invention provides a conformation-locked amphibian skin peptide derivative or a pharmaceutically acceptable salt thereof. The conformation-locked amphibian skin peptide derivative or the pharmaceutically acceptable salt thereof has a structural formula shown in the specification or a structural analogue thereof, x is derived from one amino acid in TLa, the sequence of the TLa is LLRHVVKILEKYL, and (X) 3 is composed of any continuous sequences in three TLa. The invention also provides a preparation method of the tumor microenvironment response type TLa derivative-STING agonist MSA-2 conjugate and an application of the tumor microenvironment response type TLa derivative-STING agonist MSA-2 conjugate in tumor immunotherapy. In-vivo experiments show that the conjugate can effectively inhibit primary tumor growth and distal pulmonary metastasis in a melanoma model, and tumors of part of mice can completely fade away. The conjugate disclosed by the invention is expected to be developed into a novel efficient and low-toxicity tumor immunotherapy drug.

The invention belongs to the technical field of microorganisms, and particularly discloses an anesthesia coating spore as well as a preparation method and application thereof. The coating spore comprises a spore and a ferric iron-propofol coating attached to the body surface of the spore, and the coating is formed through metal-phenol complexing and pi-pi stacking. The spores are dormant bodies of collagenase-producing bacteria. The coating spores can be selectively germinated and colonized in a tumor hypoxic microenvironment, Fe < 3 + > can promote bacterial proliferation, loaded propofol inhibits tumor metastasis by inhibiting migration and invasion of tumor cells, generated collagenase degrades tumor collagen, meanwhile, Fe < 3 + > is reduced into Fe < 2 + > by glutathione in the cells, and the coating spores can be selectively colonized in the tumor hypoxic microenvironment. Therefore, a powerful Fenton reaction is induced to trigger lipid peroxidation, and ferroptosis of tumor cells is initiated. The injection of the anesthetic coating spores in the single tumor not only effectively ablates the primary tumor and inhibits the growth of the tumor, but also significantly inhibits the distal pulmonary metastasis of the in-situ tumor model.

This invention belongs to the field of biomedical technology and discloses the application of olaparib in combination with taquimod in the preparation of anti-tumor metastasis drugs. This invention is the first to discover that olaparib and taquimod, even at low concentrations (i.e., concentrations that do not affect tumor cell proliferation), can effectively inhibit the invasion and metastasis of breast cancer cells, exhibiting high safety. Furthermore, when olaparib and taquimod are used in combination, the inhibitory effect on breast cell invasion and metastasis shows a synergistic enhancement trend, with significantly better efficacy than single-drug therapy, overcoming the limitations of monotherapy. Moreover, the combination of olaparib and taquimod can effectively inhibit lung metastasis of breast cancer, providing a new theoretical basis and medication regimen for anti-metastasis treatment of breast cancer.

The present invention belongs to the technical field of cancer immunotherapy and specifically relates to a combination-therapy drug and composition of a cholesterolylated TLR7 liposome and a TLR9 agonist and use thereof. Toll-like receptor agonists have poor targeting capability and significant side effects in anti-tumor treatment, and, as monotherapy in anti-tumor treatment, have limited efficacy. To address the described issues, the present invention provides the cholesterolylated TLR7 liposome, which is prepared from the cholesterol-modified 1V209 molecule 1V209-Cho, a lipid component, and cholesterol, and uses the liposome in combination with the TLR9 agonist to treat tumors. Animal results show that the combination of the liposome and the TLR9 agonist, when administered as nasal drops or by means of intramuscular injection, can significantly inhibit pulmonary metastasis of cervical cancer cells and melanoma cells, indicating that using the cholesterolylated liposome 1V209-Cho-Lip in combination with the TLR9 agonist to treat tumors is a strategy with great potential.

The invention relates to a composition for blocking lactic acid efflux and enhancing tumor photoimmunotherapy as well as a preparation method and application of the composition, and the composition co-delivers an MCT4 inhibitor cyclostin and a photodiagnosis and treatment agent L8BO through a lactic acid metabolism checkpoint blocking strategy of a targeted monocarboxylic acid transporter 4 (MCT4) so as to enhance photoimmunotherapy. The composition L8-atSY has a strong intramolecular charge transfer effect, an optimized singlet-triplet energy gap and an excellent light capture capability, realizes simultaneous generation of I-type and II-type active oxygen, has a total active oxygen yield up to 503 times within the illumination time of 5 minutes, and also has photothermal conversion efficiency up to 46.2%. Under the trigger of lactic acid efflux blocking induction intracellular acidification, the nanoparticles based on the composition show an excellent tumor inhibition effect, almost completely inhibit primary tumors (the inhibition rate is 99.6%), significantly inhibit distal tumors (the inhibition rate is 68.6%), and reduce pulmonary metastasis at the same time.

The invention relates to application of chlorin-loaded rare earth upconversion nanoparticles and an anti-tumor and anti-inflammatory drug, and relates to the field of biological medicines. The chlorin-loaded rare earth up-conversion nanoparticles are used for preparing anti-tumor or / and anti-inflammatory drugs. The chlorin-loaded rare earth up-conversion nanoparticles disclosed by the invention do not generate toxicity to normal cells in a concentration range of 31.25-500mu g / ml, and can effectively inhibit migration of tumor cells and inflammation related mechanisms; the tumor targeting agent has no toxicity to mice within 120 mg / kg in mice, can target tumor sites and reach lungs through blood circulation, and 20 mg / kg of the tumor targeting agent can significantly inhibit tumor volume and tumor pulmonary metastasis.

The present invention discloses a copper-based metabolic regulation nanomaterial, its preparation method and application, and belongs to the technical field of tumor drug preparation. The copper-based metabolic regulation nanomaterial provided by the present invention has a ferroptosis / copper death inducer as the core and a liposome loaded with a glycolysis / NAMPT dual inhibitor as the shell; the glycolysis / NAMPT dual inhibitor is STF-31, and the ferroptosis / copper death inducer is a copper-tannic acid ligand, which can interfere with glycolysis and inhibit NAD + Metabolism, inducing ferroptosis / copper death and reversing the immunosuppressive tumor microenvironment, significantly inhibiting tumor growth and lung metastasis, providing a feasible treatment model for synergistic cancer treatment with good anti-tumor efficacy and practical application value.

The invention provides an application of an HOXA3 gene as a target spot in screening and treating drugs for hepatocellular carcinoma. Through single-cell multi-omics analysis, the HOXA3 is found to be remarkably and highly expressed in liver cancer tissues and is closely related to poor prognosis of patients. Mechanism research shows that HOXA3 promotes tumor proliferation and metastasis through transcriptional up-regulation of YAP1 and RHOA, and an FGF19-FGFR4 / beta-catenin signal channel positively regulates the expression of HOXA3. The invention verifies that the combined application of the YAP1 inhibitor Verteporfin and the RHOA inhibitor Rhosin can significantly inhibit the HOXA3-mediated liver cancer progress, in-vivo experiments show that the tumor volume is reduced by 68%, the lung metastasis inhibition rate reaches 83%, and an effective treatment strategy is provided for HOXA3 positive hepatocellular carcinoma.

The invention provides an anti-IL13R alpha 2 monoclonal antibody. The amino acid sequences of three heavy chain complementary determining regions H-CDR1, H-CDR2 and H-CDR3 of the monoclonal antibody are respectively as shown in SEQ ID NO. 11 to SEQ ID NO. 13; the amino acid sequences of three light chain complementary determining regions (L-CDR1, L-CDR2 and L-CDR3) of the monoclonal antibody are respectively as shown in SEQ ID NO. 23 to SEQ ID NO. 25. The invention also provides application of the monoclonal antibody in preparation of drugs for treating triple negative breast tumor or triple negative breast tumor pulmonary metastasis. Tests find that the IL13Ralpha2 monoclonal antibody 1-3C-1 can inhibit the multiplication capacity of triple-negative breast cancer cells in vitro, the migration and invasion capacity of the triple-negative breast cancer cells in vitro, the growth of triple-negative breast cancer in vivo and the lung metastasis of triple-negative breast cancer in vivo.

The invention belongs to the technical field of biological detection, and particularly relates to a biomarker for detecting intestinal cancer or evaluating lung metastasis risk of intestinal cancer and application of the biomarker. Based on the biomarker serum SEMA3C, the AUC of intestinal cancer pulmonary metastasis evaluation reaches 0.867, the sensitivity is 90.2%, the specificity is 70.7%, and compared with a traditional tumor marker, the biomarker is better, and can effectively perform early diagnosis on intestinal cancer pulmonary metastasis.

The invention belongs to the related field of cancer prevention and treatment, and provides application of nicotinic acid in preparation of drugs for preventing or treating esophageal squamous carcinoma, and the drugs comprise drugs for inhibiting in-situ growth of esophageal squamous carcinoma and / or metastasis of any organ. The invention finds that high expression of FRMD8 in esophageal squamous carcinoma tissues prompts metastasis and poor prognosis. Nicotinic acid can significantly inhibit the expression level of FRMD8, thereby inhibiting the activity of a downstream JAK1-STAT3 axis. The invention finds that the nicotinic acid can significantly inhibit the in-vitro growth and invasion migration ability of esophageal squamous carcinoma cells, and can inhibit the growth and lung metastasis of esophageal squamous carcinoma cells in a mouse model.

The invention discloses a preparation method of biodegradable alginate microspheres and a composition of the biodegradable alginate microspheres. The biodegradable alginate microspheres are used for treating at least one of the following diseases: hepatocellular carcinoma, colorectal hepatic metastasis, parangganglioma hepatic metastasis, neuroendocrine hepatic metastasis, gastrointestinal hepatic metastasis, mammary gland hepatic metastasis, melanoma hepatic metastasis, pancreatic hepatic metastasis, bile duct cancer hepatic metastasis, colorectal pulmonary metastasis and kidney pulmonary metastasis. Cirrhosis-associated thrombocytopenia, metastatic extrahepatic cholangiocarcinoma, glioblastoma, renal cell carcinoma, prostate cancer, and hysteromyoma. In some embodiments, the preparation method of the biodegradable alginate microspheres can utilize a microfluidic box.

The invention discloses a chemotherapeutic drug-loaded embolism microsphere as well as a preparation method and application of the chemotherapeutic drug-loaded embolism microsphere. The preparation method comprises the following steps: carrying out free radical polymerization cross-linking curing on a water-phase material containing macromolecules with cross-linking groups and an oil-phase material through a micro-channel pipeline to obtain microspheres; and mixing the microspheres with a chemotherapeutic drug to obtain the embolism microspheres carrying the chemotherapeutic drug. In transarterial chemical embolism treatment, by using the embolism microspheres loaded with the chemotherapeutic drugs, liver tumors can be effectively embolized, meanwhile, the entrapped chemotherapeutic drugs are slowly released, the growth of in-situ liver cancer is remarkably inhibited, and the occurrence of pulmonary metastasis is effectively reduced. The embolism microsphere capable of loading the chemotherapeutic drugs has the advantages of being high in safety, convenient to prepare, good in embolism effect and the like, efficient entrapment and controllable release of various chemotherapeutic drugs can be achieved, the embolism microsphere has large transformation potential in the field of transarterial chemical embolism of liver cancer, and development of vascular embolism agents is expected to be promoted.

The invention discloses immune cell targeted lipid nanoparticles as well as a screening method and application thereof, and particularly discloses application of a compound as shown in a formula (I) or pharmaceutically acceptable salt, prodrug or stereoisomer thereof in targeted immune cells, LNP-mRNA compound delivery linear mRNA and annular mRNA can be stably expressed in vivo, and the immune cell targeted lipid nanoparticles can be applied to immune cells. Various immune cells can be edited at the same time, and the treatment effect in a lung metastasis model and a solid tumor model is remarkable; meanwhile, the invention discloses a method for screening lipid nanoparticles in vitro and a method for screening lipid nanoparticles suitable for delivery of mRNA (messenger Ribonucleic Acid) of various immune cells in vivo, and solves the problems of high primary cell dosage and long primary cell extraction time caused by direct screening of primary macrophages.